---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022760"
form_type: "8-K"
ticker: "CDT"
cik: "0001896212"
company_name: "CDT Equity Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:49:26.521247+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Conduit renames to CDT Equity Inc., appoints James Bligh permanent CFO, adds 2M shares to incentive plan

## Summary
- Name change from Conduit Pharmaceuticals Inc. to CDT Equity Inc. effective Aug 5, 2025; ticker remains CDT; no shareholder vote required.
- James Bligh, co-founder and interim CFO since May 2024, appointed permanent CFO; compensation unchanged; retains board seat.
- Stockholders approved amendment to 2023 Stock Incentive Plan adding 2,000,000 authorized shares for awards.
- Press release details strategic shift: AI-driven drug repurposing via Sarborg partnership, animal health collaboration with Manoira, and evaluation of cryptocurrency treasury reserve strategy.
- All five director nominees elected: Andrew Regan, Freda Lewis-Hall, James Bligh, Chele Chiavacci Farley, Simon Fry; auditor CBIZ CPAs P.C. ratified.

## SEC filing metadata
- accession: 0001641172-25-022760
- form_type: 8-K
- ticker: CDT
- cik: 0001896212
- company_name: CDT Equity Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/0001641172-25-022760-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022760
- JSON: https://secwatch.observer/filing/0001641172-25-022760.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022760.txt

## Key facts
- Governance Changes
  CDT Equity Inc.: Amended certificate of incorporation to change company name from Conduit Pharmaceuticals Inc. to CDT Equity Inc (effective 2025-08-05).
  - Change: charter amendment
  - Effective: 2025-08-05
  source text: On August 5, 2025, the Company filed an amendment to its Second Amended and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Conduit Pharmaceuticals Inc.” to “CDT Equity Inc.” (the “ Name Change ”), which became effective at 5 p.m. Eastern Time on August 5, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/0001641172-25-022760-index.htm
- Governance Changes
  CDT Equity Inc.: Amended and restated bylaws to reflect name change and update quorum description per a prior amendment (effective 2025-08-05).
  - Change: bylaw amendment
  - Effective: 2025-08-05
  source text: In connection with the Name Change, the Company also amended and restated its Amended and Restated Bylaws (as amended, the “ Second Amended and Restated Bylaws ”) on August 5, 2025 to reflect the Name Change.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1896212/000164117225022760/0001641172-25-022760-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.